Short Interest in INmune Bio, Inc. (NASDAQ:INMB) Increases By 7.8%

INmune Bio, Inc. (NASDAQ:INMB) saw a significant growth in short interest in December. As of December 15th, there was short interest totalling 4,000,000 shares, a growth of 7.8% from the November 30th total of 3,710,000 shares. Based on an average trading volume of 232,100 shares, the short-interest ratio is presently 17.2 days.

Institutional Investors Weigh In On INmune Bio

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp grew its position in shares of INmune Bio by 124.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock valued at $517,000 after acquiring an additional 32,511 shares during the period. Rhumbline Advisers acquired a new position in shares of INmune Bio during the 2nd quarter worth approximately $121,000. Marshall Wace LLP increased its stake in INmune Bio by 332.1% during the 2nd quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock worth $1,022,000 after acquiring an additional 89,091 shares during the period. CVI Holdings LLC acquired a new position in INmune Bio in the 2nd quarter valued at $5,260,000. Finally, Fermata Advisors LLC lifted its position in shares of INmune Bio by 25.2% during the 3rd quarter. Fermata Advisors LLC now owns 42,730 shares of the company’s stock valued at $230,000 after acquiring an additional 8,590 shares during the period. Institutional investors own 12.72% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Alliance Global Partners began coverage on shares of INmune Bio in a research report on Monday, October 21st. They issued a “buy” rating and a $20.00 price objective on the stock. Raymond James started coverage on INmune Bio in a report on Friday, September 27th. They issued an “outperform” rating and a $18.00 price target on the stock.

INmune Bio Stock Up 0.4 %

NASDAQ INMB opened at $4.67 on Thursday. INmune Bio has a 12-month low of $4.32 and a 12-month high of $14.74. The firm’s 50 day moving average is $5.19 and its 200-day moving average is $6.26. The company has a market capitalization of $103.53 million, a PE ratio of -2.14 and a beta of 1.79.

INmune Bio (NASDAQ:INMB) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.11). INmune Bio had a negative return on equity of 117.48% and a negative net margin of 26,333.59%. During the same quarter in the prior year, the firm earned ($0.48) EPS. As a group, sell-side analysts expect that INmune Bio will post -2.24 EPS for the current year.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.